纤维肌痛治疗市场规模、份额和成长分析：按药物类别、分销管道和地区划分 - 产业预测，2024-2031 年

纤维肌痛治疗市场规模预计在 2022 年达到 13 亿美元，从 2023 年的 13.9 亿美元增至 2031 年的 23.9 亿美元，预计复合年增长率为 7.00%。

纤维肌痛症是一种慢性疼痛疾病，其特征是广泛的疼痛、疲劳以及睡眠不安和情绪低落等其他症状。它影响着世界上大约 2% 的成年人口，其中女性患病率高于男性。儘管进行了广泛的研究，但目前尚无法治疗方法纤维肌痛。然而，有多种治疗方法可以缓解症状并提高生活品质。治疗方法通常包括药物治疗、生活方式调整和非药物治疗。其目的是缓解疼痛、改善睡眠模式、解决心理挑战并提高您的整体幸福感。纤维肌痛治疗很复杂，需要根据您的个人需求和反应制定治疗计划。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 市场生态系统
• Start-Ups分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

纤维肌痛治疗市场：依通路分类

• 市场概况
• 医院药房
• 零售药房
• 网路药房

纤维肌痛治疗市场：依药物类别

• 市场概况
• 抗忧郁症、抗癫痫药
• 肌肉鬆弛剂
• 其他的

纤维肌痛治疗市场规模：依地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Pfizer Inc.（United States）
• Eli Lilly and Company（United States）
• Johnson & Johnson（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Daiichi Sankyo Company, Limited（Japan）
• AbbVie Inc.（United States）
• Pfizer（United States）
• Boehringer Ingelheim International GmbH（Germany）
• GlaxoSmithKline plc（United Kingdom）
• AstraZeneca PLC（United Kingdom）
• Mylan NV（Netherlands）
• Sanofi SA（France）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Biogen Inc.（United States）
• Allergan plc（Ireland）
• Bristol Myers Squibb（United States）
• Celgene Corporation（United States）

Fibromyalgia Treatment Market size was valued at USD 1.3 billion in 2022 and is poised to grow from USD 1.39 billion in 2023 to USD 2.39 billion by 2031, growing at a CAGR of 7.00% in the forecast period (2024-2031).

Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, and additional symptoms such as sleep disturbances and mood swings. It affects approximately 2% of the global adult population, with a higher prevalence among women than men. Despite extensive research, there is currently no cure for fibromyalgia. However, various treatments are available to help alleviate symptoms and enhance the quality of life for those affected. Treatment approaches typically include medications, lifestyle adjustments, and non-pharmacological therapies. The objective is to alleviate pain, improve sleep patterns, address psychological challenges, and enhance overall well-being. The complex nature of fibromyalgia management underscores the need for personalized treatment plans tailored to individual needs and responses.

Top-down and bottom-up approaches were used to estimate and validate the size of the Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Fibromyalgia Treatment Market Segmental Analysis

Global Fibromyalgia Treatment Market is segmented based on drug class, distribution channels, and region. Based on drug class, the market is segmented into antidepressants, antiepileptic, muscle relaxants, and others. Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Drivers of the Fibromyalgia Treatment Market

Several factors contribute to the expansion of the global fibromyalgia treatment market, primarily driven by the rising prevalence of fibromyalgia on a global scale. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), approximately five million adults aged 18 and older are affected by fibromyalgia in the United States alone. Notably, 80 to 90 percent of fibromyalgia patients are women, underscoring the significant impact of this condition on the female population. Increased awareness of fibromyalgia and advancements in diagnostic capabilities are also fostering greater recognition of the disorder worldwide.

Restraints in the Fibromyalgia Treatment Market

The scarcity of drugs approved specifically for treating fibromyalgia has resulted in only three available options. Consequently, there is growing reliance on off-label medications and personalized antidepressants to manage the disease's symptoms. In June 2019, Pfizer's loss of patent protection for Lyrica, the initial drug approved for fibromyalgia treatment, had a profound impact on its market revenue. The expiration of patent protection allowed generic versions of Lyrica to enter the market, intensifying competition and leading to a subsequent decline in overall market value.

Market Trends of the Fibromyalgia Treatment Market

Major players in the global fibromyalgia treatment market are actively pursuing innovative therapies to sustain or expand their market presence. The introduction and approval of emerging treatments for fibromyalgia are expected to significantly contribute to market growth during the forecast period. One notable example is galcanezumab, developed by Eli Lilly & Co., which is currently undergoing Phase IV clinical trials from January 2021 to December 2021 specifically for treating fibromyalgia. This expansion into new indications underscores the commitment of leading pharmaceutical companies to address the complex and evolving requirements of fibromyalgia patients.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Fibromyalgia Treatment Market by Distribution Channels

• Market Overview
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Global Fibromyalgia Treatment Market by Drug class

• Market Overview
• Antidepressants, Antiepileptic
• Muscle relaxants
• Others

Global Fibromyalgia Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments